SCHEMBL14906702

SCHEMBL14906702

Nc1ccc2ncc(-c3cccnc3)cc2c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 3/20 0.67
PDGFRB P09619 3/20 0.61
PDGFRA P16234 3/20 0.61
EGFR P00533 2/20 0.61
MAPT P10636 2/20 0.57
HTT P42858 2/20 0.57
AXL P30530 2/20 0.56
MEN1 O00255 1/20 0.56
PSIP1 O75475 1/20 0.56
MKNK1 Q9BUB5 1/20 0.56
MKNK2 Q9HBH9 1/20 0.56
ALDH1A1 P00352 2/20 0.53
HSP90AA1 P07900 2/20 0.53
HSP90AB1 P08238 2/20 0.53
KDM4E B2RXH2 1/20 0.53
TP53 P04637 1/20 0.53
TSHR P16473 1/20 0.53
CASP1 P29466 1/20 0.53
ATM Q13315 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14906625 0.83 TLR9 (0.58) CYP2A6PDGFRBPDGFRAEGFRMAPT
SCHEMBL14906701 0.82 PDGFRB (0.62) CYP2A6PDGFRBPDGFRAEGFRMAPT
SCHEMBL13304740 0.80 CYP11B2 (0.71) CYP2A6MAPTHTTAXLMEN1
SCHEMBL3612716 0.80 CYP2A6 (1.00) CYP2A6PDGFRBPDGFRAEGFRMAPT
SCHEMBL29746239 0.80 CYP2A6 (1.00) CYP2A6PDGFRBPDGFRAEGFRMAPT
SCHEMBL29832072 0.78 CYP2A6 (0.93) CYP2A6PDGFRBPDGFRAEGFRMAPT
SCHEMBL28031300 0.77 MAPT (0.52) CYP2A6EGFRMAPTHTTAXL
SCHEMBL31060290 0.76 PDGFRB (1.00) CYP2A6PDGFRBPDGFRAEGFRMAPT
SCHEMBL14906805 0.76 RAB9A (0.62) CYP2A6PDGFRBPDGFRAEGFRALDH1A1
SCHEMBL30604173 0.73 NPC1 (0.75) CYP2A6PDGFRBPDGFRAEGFRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10039759-B2 Quinolines as FGFR kinase modulators ASTEX THERAPEUTICS LTD (GB) 2018-08-07 US disclosed
US-10039759-B2 Quinolines as FGFR kinase modulators ASTEX THERAPEUTICS LTD (GB) 2018-08-07 US disclosed
EP-2776397-B1 QUINOLINES AS FGFR KINASE MODULATORS ASTEX THERAPEUTICS LTD (GB) 2017-11-29 EP disclosed
US-9439896-B2 Quinolines as FGFR kinase modulators ASTEX THERAPEUTICS LTD (GB) 2016-09-13 US disclosed
US-9439896-B2 Quinolines as FGFR kinase modulators ASTEX THERAPEUTICS LTD (GB) 2016-09-13 US disclosed
US-20140296236-A1 QUINOLINES AS FGFR KINASE MODULATORS ASTEX THERAPEUTICS LIMITED (GB) 2014-10-02 US disclosed
US-20140296236-A1 QUINOLINES AS FGFR KINASE MODULATORS ASTEX THERAPEUTICS LIMITED (GB) 2014-10-02 US disclosed
WO-2013061074-A1 QUINOLINES AS FGFR KINASE MODULATORS ASTEX THERAPEUTICS LIMITED (GB) 2013-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10039759-B2 Quinolines as FGFR kinase modulators FGFR1, FGFR3, FGFR2 CYP2A6 1702/4885PDGFRB 38/4885PDGFRA 45/4885
US-20140296236-A1 QUINOLINES AS FGFR KINASE MODULATORS FGFR1, FGFR2, FGFR3 CYP2A6 1840/4885PDGFRB 36/4885PDGFRA 41/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.